A Phase 1 interventional study of IV Tedizolid Phosphate and Oral Suspension Tedizolid Phosphate in Gram-Positive Infections, sponsored by Merck Sharp & Dohme LLC. Completed at 30 sites in 5 countries. Open to participants aged 1 Day to 24 Months. Per ClinicalTrials.gov, last updated 2025-02-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this study are to describe the single-dose, and multiple dose pharmacokinetics (PK) of intravenous (IV) tedizolid phosphate, or a single dose oral suspension of tedizolid phosphate, when administered to pediatric participants, full-term neonates, and preterm neonates.
Per protocol, PK analysis in Part A Group 1 will be conducted across ages in Cohorts 1 and 2 combined: Part A Group 1 Cohort 1 + Cohort 2: 28 days to \<24 months.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric participants 28 days to \<6 months of age will receive a single dose (SD) intravenous (IV) infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
Drug: IV Tedizolid Phosphate
Pediatric participants 6 months to \<24 months of age will receive an SD IV infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
Drug: IV Tedizolid Phosphate
Full term (FT) neonates from birth to \<28 days of age will receive an SD IV infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
Drug: IV Tedizolid Phosphate
FT neonates from birth to \<28 days of age will receive multiple dose (MD) IV infusions of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg, administered twice daily for 3 days.
Drug: IV Tedizolid Phosphate
Preterm (PT) neonates from birth to \<28 days of age will receive an SD IV infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
Drug: IV Tedizolid Phosphate
PT neonates from birth to \<28 days of age will receive MD IV infusions of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg, administered twice daily for 3 days.
Drug: IV Tedizolid Phosphate
Pediatric participants 28 days to \<24 months of age will receive an SD oral suspension of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
Drug: Oral Suspension Tedizolid Phosphate
FT neonates from birth to \<28 days of age will receive an SD oral suspension of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
Drug: Oral Suspension Tedizolid Phosphate
PT neonates from birth to \<28 days of age will receive an SD oral suspension of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.
Drug: Oral Suspension Tedizolid Phosphate
A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
A single dose of tedizolid phosphate administered as an oral suspension.
Part A: Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Drug Concentration (AUC0-last) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration
AUC0-last of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of pharmacokinetic (PK) outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate AUC0-last for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.
Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Part A: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration
AUC0-inf of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate AUC0-inf for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.
Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Part A: Maximum Concentration (Cmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration
Cmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate Cmax for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.
Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Part A: Time to Reach Maximum Concentration (Tmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration
Tmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate Tmax for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.
Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Part A: Apparent Terminal Half-life (t½) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration
t½ of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate t½ for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.
Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Part A: AUC0-last of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration
AUC0-last of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate AUC0-last for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.
Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Part A: AUC0-inf of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration
AUC0-inf of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate AUC0-inf for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this endpoint and were excluded from this protocol-specified analysis.
Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Part A: Cmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration
Cmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate Cmax for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.
Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Part A: Tmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration
Tmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate Tmax for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.
Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Part A: t½ of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration
t½ of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate t½ for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.
Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Part A: AUC0-24 of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate [AUC0-last]
AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, AUC0-last for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.
Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Part A: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate
AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, AUC0-inf for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.
Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Part A: Cmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate
Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, Cmax for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.
Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Part A: Tmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate
Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, Tmax for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.
Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Part A: t½ of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate
t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, t½ for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.
Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Part A: AUC0-12 of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate [AUC0-last]
AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. This was analyzed in the per protocol population consisting of the subset of participants who complied with the protocol sufficiently to ensure that these data would be likely to exhibit treatment effects, based on the underlying scientific model and had data available for this endpoint. As specified in the protocol, AUC0-last for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.
Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Part A: Cmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate
Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, Cmax for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.
Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Part A: Tmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate
Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, Tmax for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.
Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Part A: AUC0-inf of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate
AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach to be used in this noncompartmental analysis would allow data collected to generate single concentration listing. However, protocol-specified PK sampling did not characterize the terminal elimination phase; therefore, AUC0-inf of tedizolid metabolite could not be estimated for multiple dose study arms (Part A Group 2 Cohort 2 and Part A Group 3 Cohort 2). As specified in the protocol, AUC0-inf for tedizolid metabolite in single dose (Part A Group 1\[Cohorts 1 and 2\],Group 2 Cohort 1, Group 3 Cohort 1; Part B\[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.
Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Part A: t½ of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate
t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach to be used in this noncompartmental analysis would allow data collected to generate single listing. However, protocol-specified PK sampling did not characterize the terminal elimination phase; therefore, t½ could not be estimated for multiple dose study arms (Part A Group 2 Cohort 2 and Part A Group 3 Cohort 2). As specified in the protocol, t½ for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.
Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Part B: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension [AUC0-last]
AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, AUC0-last for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.
Time frame: 1, 3, 5, 8, 12, and 24 hours post start of dosing
Part B: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension
AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, AUC0-inf for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.
Time frame: 1, 3, 5, 8, 12, and 24 hours post start of dosing
Part B: Cmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension
Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, Cmax for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.
Time frame: 1, 3, 5, 8, 12, and 24 hours post start of dosing
Part B: Tmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension
Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, Tmax for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.
Time frame: 1, 3, 5, 8, 12, and 24 hours post start of dosing
Part B: t½ of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension
t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, t½ for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.
Time frame: 1, 3, 5, 8, 12, and 24 hours post start of dosing
Number of Participants With an Adverse Event (AE)
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing an AE was reported for each arm.
Time frame: Up to approximately 21 days
Number of Participants That Discontinued Study Treatment Due to an AE
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants that discontinued study treatment due to an AE was reported for each arm.
Time frame: Up to approximately 3 days
This study was conducted at 30 centers in 5 countries.
| Milestone | Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months | Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 6 | 8 | 4 | 9 | 4 | 4 | 4 | 4 |
| Completed | 4 | 6 | 8 | 4 | 9 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AUC0-last of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of pharmacokinetic (PK) outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate AUC0-last for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.
| hr*μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Drug Concentration (AUC0-last) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration | NA ± NA | NA ± NA | — | NA ± NA | — | — | — | — |
AUC0-inf of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate AUC0-inf for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.
| hr*μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration | NA ± NA | NA ± NA | — | NA ± NA | — | — | — | — |
Cmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate Cmax for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.
| μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Maximum Concentration (Cmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration | NA ± NA | NA ± NA | — | NA ± NA | — | — | — | — |
Tmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate Tmax for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.
| hr | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Time to Reach Maximum Concentration (Tmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration | NA (NA to NA) | NA (NA to NA) | — | NA (NA to NA) | — | — | — | — |
t½ of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate t½ for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.
| hr | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Apparent Terminal Half-life (t½) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration | NA ± NA | NA ± NA | — | NA ± NA | — | — | — | — |
AUC0-last of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate AUC0-last for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.
| hr*μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: AUC0-last of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration | — | — | — | — | NA ± NA | — | — | — |
AUC0-inf of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate AUC0-inf for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this endpoint and were excluded from this protocol-specified analysis.
| hr*μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: AUC0-inf of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration | — | — | — | — | NA ± NA | — | — | — |
Cmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate Cmax for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.
| μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Cmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration | — | — | — | — | NA ± NA | — | — | — |
Tmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate Tmax for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.
| hr | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Tmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration | — | — | — | — | NA (NA to NA) | — | — | — |
t½ of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate t½ for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.
| hr | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: t½ of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration | — | — | — | — | NA ± NA | — | — | — |
AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, AUC0-last for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.
| hr*μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: AUC0-24 of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate [AUC0-last] | 13.6 ± 42.4 | 8.23 ± 115.9 | — | 15.6 ± 17.6 | — | — | — | — |
AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, AUC0-inf for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.
| hr*μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate | 14.3 ± 40.4 | 9.21 ± 128.2 | — | 17.8 ± 20.9 | — | — | — | — |
Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, Cmax for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.
| μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Cmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate | 2.19 ± 51.0 | 0.962 ± 71.9 | — | 1.35 ± 44.5 | — | — | — | — |
Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, Tmax for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.
| hr | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Tmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate | 1.33 (1.00 to 1.58) | 1.41 (1.00 to 2.50) | — | 1.50 (1.08 to 6.53) | — | — | — | — |
t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, t½ for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.
| hr | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: t½ of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate | 4.17 ± 47.7 | 6.63 ± 38.0 | — | 7.08 ± 41.2 | — | — | — | — |
AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. This was analyzed in the per protocol population consisting of the subset of participants who complied with the protocol sufficiently to ensure that these data would be likely to exhibit treatment effects, based on the underlying scientific model and had data available for this endpoint. As specified in the protocol, AUC0-last for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.
| hr*μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: AUC0-12 of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate [AUC0-last] | — | — | 10.5 | — | 7.48 | — | — | — |
Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, Cmax for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.
| μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Cmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate | — | — | 1.82 | — | 1.69 | — | — | — |
Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, Tmax for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.
| hr | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part A: Tmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate | — | — | 1.60 | — | 1.08 | — | — | — |
AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach to be used in this noncompartmental analysis would allow data collected to generate single concentration listing. However, protocol-specified PK sampling did not characterize the terminal elimination phase; therefore, AUC0-inf of tedizolid metabolite could not be estimated for multiple dose study arms (Part A Group 2 Cohort 2 and Part A Group 3 Cohort 2). As specified in the protocol, AUC0-inf for tedizolid metabolite in single dose (Part A Group 1\[Cohorts 1 and 2\],Group 2 Cohort 1, Group 3 Cohort 1; Part B\[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.
No measurements were reported for this outcome.
t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach to be used in this noncompartmental analysis would allow data collected to generate single listing. However, protocol-specified PK sampling did not characterize the terminal elimination phase; therefore, t½ could not be estimated for multiple dose study arms (Part A Group 2 Cohort 2 and Part A Group 3 Cohort 2). As specified in the protocol, t½ for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.
No measurements were reported for this outcome.
AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, AUC0-last for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.
| hr*μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part B: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension [AUC0-last] | — | — | — | — | — | 7.92 | 9.25 | 14.9 |
AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, AUC0-inf for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.
| hr*μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part B: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension | — | — | — | — | — | 8.36 | 9.44 | 22.1 |
Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, Cmax for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.
| μg/mL | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part B: Cmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension | — | — | — | — | — | 1.32 | 0.899 | 1.22 |
Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, Tmax for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.
| hr | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part B: Tmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension | — | — | — | — | — | 1 | 3.03 | 8 |
t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, t½ for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.
| hr | Group 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|
| Part B: t½ of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension | — | — | — | — | — | 5.73 | 3.82 | 13.4 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing an AE was reported for each arm.
| Participants | Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months | Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With an Adverse Event (AE) | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 0 | 1 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants that discontinued study treatment due to an AE was reported for each arm.
| Participants | Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months | Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants That Discontinued Study Treatment Due to an AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Up to approximately 21 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months | 0/4 (0%) | 1/4 (25%) | 0/4 (0%) |
| Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Event | Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months | Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic product effect incompleteGeneral disorders | 1/4 | 0/6 | 0/8 | 0/4 | 0/9 | 0/4 | 0/4 | 0/4 | 0/4 |
| Event | Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months | Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days |
|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/4 | 0/6 | 0/8 | 0/4 | 0/9 | 1/4 | 0/4 | 0/4 | 0/4 |
| Swelling of eyelidEye disorders | 0/4 | 0/6 | 0/8 | 0/4 | 0/9 | 0/4 | 1/4 | 0/4 | 0/4 |
| ConjunctivitisInfections and infestations | 0/4 | 0/6 | 0/8 | 0/4 | 0/9 | 1/4 | 0/4 | 0/4 | 0/4 |
| Serratia sepsisInfections and infestations | 0/4 | 0/6 | 0/8 | 0/4 | 0/9 | 1/4 | 0/4 | 0/4 | 0/4 |
| Immature granulocyte count increasedInvestigations | 0/4 | 0/6 | 0/8 | 0/4 | 0/9 | 0/4 | 0/4 | 0/4 | 1/4 |
| Jaundice neonatalPregnancy, puerperium and perinatal conditions | 0/4 | 0/6 | 0/8 | 0/4 | 0/9 | 1/4 | 0/4 | 0/4 | 0/4 |
| RashSkin and subcutaneous tissue disorders | 0/4 | 1/6 | 0/8 | 0/4 | 0/9 | 0/4 | 0/4 | 0/4 | 0/4 |
| PneumoniaInfections and infestations | 0/4 | 0/6 | 0/8 | 0/4 | 1/9 | 0/4 | 0/4 | 0/4 | 0/4 |
| Bronchopulmonary dysplasiaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/6 | 0/8 | 0/4 | 1/9 | 0/4 | 0/4 | 0/4 | 0/4 |
| Age, Continuous(Days) | Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months | Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 51.3 ± 9.9 | 420.7 ± 167.1 | 8.3 ± 9.4 | 11.8 ± 11.3 | 9.9 ± 7.9 | 2.0 ± 1.2 | 289.0 ± 165.5 | 13.0 ± 11.7 | 6.5 ± 6.4 | 88.8 ± 165.7 |
| Sex: Female, Male(Participants) | Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months | Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 5 | 1 | 3 | 2 | 2 | 0 | 1 | 18 |
| Male | 2 | 4 | 3 | 3 | 6 | 2 | 2 | 4 | 3 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months | Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 7 | 3 | 3 | 2 | 0 | 2 | 3 | 20 |
| Not Hispanic or Latino | 4 | 6 | 1 | 1 | 5 | 2 | 4 | 2 | 1 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months | Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months | Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days | Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days | Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days | Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months | Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days | Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 3 | 5 | 2 | 1 | 6 | 2 | 4 | 2 | 1 | 26 |
| More than one race | 0 | 1 | 6 | 2 | 3 | 2 | 0 | 2 | 3 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2019 to primary completion in Mar 2023, 49 months.
Results were first posted in Jul 2024, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tedizolid phosphate